The high-flow nasal cannula market is a rapidly growing segment within the medical devices industry. High-flow nasal cannulas are used to deliver a high flow of heated and humidified air/oxygen mixture to patients who require respiratory support. This technology is increasingly used in hospitals, long-term care facilities, and home healthcare settings.
According to a report by Fact.MR, the global high-flow nasal cannula market size was valued at US$ 3.1 billion in 2020 and is expected to grow at a CAGR of 11% from 2021 to 2031. The growing prevalence of respiratory diseases, such as COPD, asthma, and pneumonia, is a major factor driving the demand for high-flow nasal cannulas. The increasing adoption of these devices in emergency departments, intensive care units, and neonatal care units is also contributing to market growth.
The report also notes that the COVID-19 pandemic has further accelerated the adoption of high-flow nasal cannulas, as they have been found to be effective in managing respiratory distress in COVID-19 patients. The report predicts that the demand for high-flow nasal cannulas will continue to rise in the post-pandemic era as well. Geographically, the Asia Pacific region is expected to witness the highest growth in the high-flow nasal cannula market, driven by the growing geriatric population, increasing healthcare expenditure, and improving healthcare infrastructure in the region. North America and Europe are also significant markets for high-flow nasal cannulas, owing to the high prevalence of respiratory diseases and advanced healthcare infrastructure.
In conclusion, the high-flow nasal cannula market is poised for significant growth in the coming years, driven by the increasing prevalence of respiratory diseases, the adoption of high-flow nasal cannulas in critical care settings, and the growing use of these devices in the management of COVID-19 patients
Download Free Sample Copy of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=4777
Key Segments of High-Flow Nasal Cannula Industry Research
- By Component :
- Air/Oxygen Blenders
- Air Humidifiers
- Single Heated Tubes
- Nasal Cannulas
- Others
- By Application :
- Acute Respiratory Failure
- Chronic Obstructive Pulmonary Disease (COPD)
- Carbon Monoxide Toxicity
- Bronchiectasis
- Sleep Apnea
- Others
- By End User :
- Hospitals
- Long-term Care Centers
- Ambulatory Care Centers
- Others
- By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
High-flow Nasal Cannula Market- Key Takeaways
- Active humidifier components are projected to witness high growth, aided by innovations in technology diversification by market players.
- Chronic obstructive pulmonary disease treatment applications are gaining significant traction, supported by the massive global geriatric population.
- North America and Europe are leading high-flow nasal cannula markets, driven by favorable reimbursement and healthcare policies.
Key Companies Profiled
- Hamilton Medical
- ResMed Inc.
- TNI Medical AG
- Teleflex
- Salter Labs Inc.
- Vapotherm Inc.
- Smiths Medical, Inc.
COVID-19 Impact on High-flow Nasal Cannula Market
The coronavirus pandemic has increased the requirement for supplemental oxygen therapy manifold, owing to the unprecedented influx of patients in a small timeframe. In addition, the shortage of ventilators in healthcare facilities around the world is a major concern during the crisis period. These trends are generating major growth opportunities for high-flow nasal cannula manufacturers in the short term.
About the Report
This study offers readers a comprehensive market forecast of the high-flow nasal cannula market. Global, regional and country-level analysis of the top industry trends impacting the high-flow nasal cannula market is covered in this FACT.MR study. The report offers insights on the high-flow nasal cannula market on the basis of component (oxygen blend, air humidifier, single heated tube, nasal cannula, and others), application (acute respiratory failure, chronic obstructive pulmonary disease, carbon monoxide toxicity, bronchiectasis, sleep apnea, acute respiratory failure, and others), and end user (hospital, long term care center, ambulatory care center, tomosynthesis, and others), across five regions (North America, Latin America, Europe, Asia Pacific, and MEA).
